Back to search

Poland· PL-100156242

Depakine Chronosphere 100

A valproic acid product containing natrii valproas + acidum valproicum, registered in Poland by Sanofi Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC N03AG01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDepakine Chronosphere 100ATCN03AG01REGISTER NO.PL-100156242PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Valproic acid is registered in 16 of 19 countries.

Countries holding a registration under ATC N03AG01 (valproic acid), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Valproic acid · ATC N03AG01

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of valproic acid costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Valproic acid · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1.61
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Natrii valproas + Acidum valproicum
Manufacturer
Sanofi Sp. z o.o.
Country
Poland (PL)
ATC code
N03AG01
ATC class
Valproic acid
Defined daily dose
1.5 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • gtin
    05909990425693
    30 sasz.po 303 mg
    PLN 8.27

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for valproic acid.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Valproic acid · interactions on record

391 records

  • 9 severe
  • 132 moderate
  • 23 minor
  • 189 info

Most severe, free to view

  • Glycerol phenylbutyrateA16AX09severe
  • BexaroteneL01XF03severe
  • VorinostatL01XH01severe
  • BexarotenL01XX25severe

38 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Valproic acid in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All valproic acid products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Depakine Chrono Retard, Depakine Chronosphere
  • Belgium · Depakine Chrono, Valproate Retard Eg
  • Bulgaria · Депакин Хроно
  • Cyprus · Depakine Chrono
  • Czechia · Depakine Chrono, Valproat
  • Germany · Ergenyl Chrono, Orfiril
  • Estonia · Depakine Chrono
  • Spain · Ácido Valproico Aurovitas, Depakine Crono
  • Finland · Deprakine
  • France · Depakine Chrono, Micropakine L.P.
  • United Kingdom (Northern Ireland) · Alprolep 200mg Prolonged-Release Tablets, Alprolep 300mg Prolonged-Release Tablets
  • Greece · Depakine Chrono, Depakine Chrono (Sphere)
  • Croatia · Depakine Chrono
  • Hungary · Depakine Chrono
  • Ireland · Epilim Chrono, Epilim Chronosphere
  • Italy · Acido Valproico E Sodio Valproato Eg, Acido Valproico E Sodio Valproato Ratiopharm
  • Lithuania · Depakine Chrono, Depakine Chronosphere
  • Luxembourg · Depakine Chrono, Valproate Retard Eg
  • Latvia · Depakine Chrono
  • Malta · Epilim Chrono
  • Netherlands · Depakine Chrono, Depakine Chronosphere
  • Portugal · Ácido Valpróico Aurovitas, Ácido Valpróico Generis
  • Romania · Depakine Chrono
  • Sweden · Ergenyl Retard
  • Slovenia · Depakine Chrono
  • Slovakia · Depakine Chrono, Valpro Chrono

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/12339e23-3ba3-447e-aa15-88bcfe00cf18
GET /v1/drugs/12339e23-3ba3-447e-aa15-88bcfe00cf18?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Granulat o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "(66,66 mg + 29,03 mg)/sasz.",
  "packaging": "05909990425693 ¦ Rp ¦ 31589\n30 sasz. 100 mg",
  "substance": "Natrii valproas 66.66 mg + Acidum valproicum 29.03 mg",
  "common_name": "Natrii valproas + Acidum valproicum",
  "pl_product_id": "100156242",
  "pozwolenie_nr": "11950",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about valproic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.